---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-016611"
form_type: "8-K"
ticker: "NEPH"
cik: "0001196298"
company_name: "NEPHROS INC"
filed_at: "2021-07-12T23:59:59+00:00"
generated_at: "2026-06-30T05:58:44.099256+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nephros acquires GenArraytion for $1.2M in stock; gains PCR pathogen detection tech

## Summary
- Purchase price of $1.2M paid via 123,981 shares of Nephros common stock.
- 50% of shares subject to forfeiture until intellectual property transition services completed.
- Nephros to pay royalties on net sales of GenArraytion products over five years.
- Registration statement covering issued shares must be filed within 60 days.
- GenArraytion CEO Dr. Schaudies partners with Nephros VP Dr. Smith on product integration.

## SEC filing metadata
- accession: 0001493152-21-016611
- form_type: 8-K
- ticker: NEPH
- cik: 0001196298
- company_name: NEPHROS INC
- filed_at: 2021-07-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1196298/000149315221016611/0001493152-21-016611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1196298/000149315221016611/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-016611
- JSON: https://secwatch.observer/filing/0001493152-21-016611.json
- Plain text: https://secwatch.observer/filing/0001493152-21-016611.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.